US equities |
NVDA $236.64 ▲+1.15% SPCX $166.69 ▲+4.86% MU $1,067.24 ▼-0.71% TSLA $377.14 ▲+1.77% MSFT $527.18 ▲+1.86% INTC $117.31 ▼-1.69% SNDK $1,731.50 ▲+0.67% META $741.88 ▲+1.90%
FinancialContent

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative (NQ:XOMAO)

25.00 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative

< Previous 1 2 3 Next >
News headline image
XOMA Royalty Announces Closing of Its Acquisition by Ligand
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (NASDAQ:XOMAO) Surges as a Top Growth Stock Candidate Under Navellier's Little Book Strategy ↗
Via Chartmill
News headline image
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (NASDAQ:XOMAO) Checks All Eight Boxes in Navellier’s Little Book Growth Screen ↗
Via Chartmill
XOMA Royalty Corp (NASDAQ:XOMAO) Stands Out in a High-Growth Stock Screen ↗
Via Chartmill
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Investor Conferences in March
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right 
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces CFO Transition
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value Right 
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA Royalty adds milestone and royalty economics associated with two partnered assets 
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
From XOMA Royalty Corporation; BioInvent
Via GlobeNewswire
< Previous 1 2 3 Next >